Trulicity (Dulaglutide) – Clinical Overview

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist indicated for adults and children ≥10 years with type 2 diabetes to improve glycemic control and reduce cardiovascular events in high-risk adults. 1

Indications

Type 2 Diabetes Management

Dulaglutide is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. 1
Dulaglutide reduces the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. 1

Preferred Patient Populations

Prioritize dulaglutide in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, as GLP-1 receptor agonists reduce MACE by approximately 20–26%. 2
Dulaglutide is specifically recommended for patients with chronic kidney disease (eGFR 20–60 mL/min/1.73 m² and/or albuminuria) to slow CKD progression and lower cardiovascular risk. 3
Consider dulaglutide for patients with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities) who require both glycemic control and weight loss. 3

Dosing Schedule

Adult Dosing

Start dulaglutide at 0.75 mg subcutaneously once weekly. 1, 3
After 4 weeks, increase to 1.5 mg once weekly if additional glycemic control is needed and the lower dose is well-tolerated. 1, 3
If further glycemic control is required, increase the dosage in 1.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 4.5 mg once weekly. 1

Pediatric Dosing (≥10 years)

Start at 0.75 mg subcutaneously once weekly. 1
If additional glycemic control is needed, increase to the maximum recommended dose of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dose. 1

Administration Details

Inject dulaglutide subcutaneously in the abdomen, thigh, or upper arm once weekly, any time of day, with or without food. 1, 3
Rotate injection sites with each dose. 1
The weekly administration day can be changed if at least 3 days (72 hours) have passed since the last dose. 1, 3

Missed Dose Management

If a dose is missed and there are at least 3 days (72 hours) until the next scheduled dose, administer the missed dose as soon as possible. 1
If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. 1
If 2 consecutive doses are missed, clinical judgment is required; resuming at the same dose can be considered if the patient tolerated the medication well. 3
If 3 or more consecutive doses are missed, consider restarting the titration schedule. 3

Contraindications

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). 1, 3
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 1, 3
Serious hypersensitivity reaction to dulaglutide or any product component, including anaphylactic reactions and angioedema. 1

Relative Cautions

History of pancreatitis – dulaglutide has not been studied in patients with a history of pancreatitis; consider other antidiabetic therapies in these patients. 1
Severe gastrointestinal disease, including severe gastroparesis – dulaglutide has not been studied in these patients and is therefore not recommended. 1

Adverse Effects

Common Gastrointestinal Effects

Nausea occurs in approximately 20% of patients on dulaglutide 1.5 mg, diarrhea in approximately 17%, and vomiting in a smaller percentage. 3
These gastrointestinal events are usually mild-to-moderate, transient, and diminish over time. 3
The 0.75 mg starting dose reduces the incidence of gastrointestinal adverse events compared to starting at 1.5 mg. 3

Serious Adverse Events

Monitor for pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), and acute kidney injury secondary to dehydration from gastrointestinal side effects. 3
Instruct patients to report persistent severe abdominal pain, as this may indicate pancreatitis; discontinue dulaglutide immediately if pancreatitis is suspected. 3

Hypoglycemia Risk

Dulaglutide has a low inherent risk of hypoglycemia when used as monotherapy due to its glucose-dependent mechanism of action. 4, 5, 6
When combined with insulin or sulfonylureas, the risk of hypoglycemia increases significantly; reduce or discontinue sulfonylureas and reduce basal insulin by approximately 20% when initiating dulaglutide. 3

Thyroid C-Cell Tumors

In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. 1
It is unknown whether dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. 1
Counsel patients regarding the potential risk of MTC and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). 1
Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with dulaglutide. 1

Monitoring Recommendations

Baseline Assessment

Obtain baseline HbA1c and fasting glucose to set individualized glycemic targets (generally <7% for most adults). 3
Measure estimated glomerular filtration rate (eGFR); dulaglutide requires no dose adjustment across all CKD stages, including eGFR <30 mL/min/1.73 m². 3
Document history of pancreatitis; dulaglutide may be used with caution because a causal link has not been definitively established. 3
Assess cardiovascular disease status – dulaglutide is preferred in patients with established atherosclerotic CVD or high CVD risk. 3
Screen for personal or family history of medullary thyroid carcinoma or MEN 2 – these are absolute contraindications. 3

Ongoing Monitoring

Re-assess HbA1c, fasting glucose, body weight, and blood pressure at 12–16 weeks after reaching the maintenance dose. 3
Continue monitoring HbA1c, weight, blood pressure, and cardiovascular risk factors every 3–6 months thereafter. 3
Monitor for signs and symptoms of pancreatitis (persistent severe abdominal pain) and gallbladder disease. 3
Monitor renal function, particularly in patients with chronic kidney disease who report severe gastrointestinal reactions, as dehydration may precipitate acute kidney injury. 3

Treatment Response Evaluation

If HbA1c remains >7% after approximately 3 months on the maximum tolerated dose, consider adding or intensifying other glucose-lowering medications. 3
If patients fail to achieve glycemic targets, metabolic surgery may be evaluated if BMI criteria are met and medical management is insufficient. 3

Special Populations

Renal Impairment

No dose adjustment is required for dulaglutide across all stages of chronic kidney disease, including eGFR <30 mL/min/1.73 m² and end-stage renal disease. 3, 7
Dulaglutide reduces albuminuria and slows eGFR decline, making it a preferred agent for patients with CKD. 3
Unlike exenatide or lixisenatide, dulaglutide is safe in patients with eGFR <30 mL/min/1.73 m². 7

Hepatic Impairment

No dose adjustment is required for any severity of hepatic disease, as dulaglutide is not primarily cleared by the liver. 3

Elderly Patients

Age alone does not mandate dose changes; elderly patients have been studied without additional safety concerns. 3

Pregnancy and Lactation

Dulaglutide is contraindicated in pregnancy and breastfeeding based on animal studies showing thyroid C-cell tumors. 1

Concomitant Medication Management

Insulin

When initiating dulaglutide in patients on basal insulin, reduce the insulin dose by approximately 20% to prevent hypoglycemia. 3
For patients with HbA1c <8%, consider a more aggressive 30% reduction in insulin dose. 3

Sulfonylureas

Reduce sulfonylurea dose by approximately 50% or discontinue entirely before starting dulaglutide to avoid additive hypoglycemia. 3

DPP-4 Inhibitors

Stop all DPP-4 inhibitors (e.g., sitagliptin, linagliptin) before dulaglutide initiation, as concurrent use provides no additional glycemic benefit. 3

Other GLP-1 Receptor Agonists

Dulaglutide should not be used with other GLP-1 receptor agonists, as this offers no additional benefit and increases adverse effects. 3

Efficacy

Glycemic Control

Dulaglutide 1.5 mg once weekly lowers HbA1c by approximately 1.1–1.4% from baseline. 3
Dulaglutide 1.5 mg demonstrates superiority over metformin, sitagliptin, exenatide twice daily, and insulin glargine, and is non-inferior to liraglutide 1.8 mg daily. 3, 8
In the AWARD trials, dulaglutide 1.5 mg added to various oral antihyperglycemic regimens significantly reduced HbA1c by 1.3–1.6% at 6 months, with 39–61% of patients achieving HbA1c ≤6.5% and 52–76% achieving HbA1c <7%. 9

Weight Loss

Dulaglutide 1.5 mg, but not 0.75 mg, is associated with consistent reductions in body weight from baseline. 4
Significant reductions in body weight (0.8–2.9 kg) were observed across all oral antihyperglycemic background regimens at 6 months. 9

Cardiovascular Outcomes

In the REWIND cardiovascular outcomes trial, dulaglutide was associated with a significant reduction in the risk of MACE (primary composite outcome comprising CV death, non-fatal myocardial infarction, or non-fatal stroke) at a median of 5.4 years' follow-up. 6
GLP-1 receptor agonists, including dulaglutide, reduce MACE by approximately 20–26% in patients with established cardiovascular disease. 3

Common Pitfalls to Avoid

Do not skip the initial 0.75 mg starting dose, as it is essential to minimize gastrointestinal side effects that can cause treatment discontinuation. 3
Do not escalate doses more rapidly than every 4 weeks; rapid titration increases the risk of intolerable gastrointestinal adverse events. 3
Do not postpone GLP-1 receptor agonist initiation until multiple oral agents have failed; early use in appropriate candidates (obesity, CKD, cardiovascular risk) yields better outcomes. 3
Do not discontinue metformin when starting dulaglutide unless a specific contraindication exists. 3
Do not overlook the need to reduce or stop sulfonylureas, as their combination with dulaglutide markedly increases hypoglycemia risk. 3
Do not prescribe dulaglutide to patients with a personal or family history of MTC or MEN 2 – these are absolute contraindications. 3
Do not assume renal dose adjustment is necessary; dulaglutide dosing remains unchanged across all CKD stages. 3

Perioperative Considerations

Consider holding dulaglutide for one week before elective surgery due to delayed gastric emptying effects, though evidence on aspiration risk with long-term use remains uncertain. 7
The half-life of dulaglutide ranges from 4.5 to 4.7 days depending on dose, which may inform perioperative management decisions. 7
GLP-1 receptor agonists, including dulaglutide, are associated with delayed gastric emptying, raising theoretical concerns about pulmonary aspiration risk during anesthesia. 7

Key Advantages

Once-weekly dosing improves adherence compared to daily injectable therapies. 5, 6
Durable glycemic efficacy maintained up to 2 years in long-term studies. 4, 6
Beneficial effects on body weight and cardiovascular outcomes. 6
Low inherent risk of hypoglycemia when used as monotherapy. 4, 5, 6
No dose adjustment required for renal or hepatic impairment. 3, 7
Convenient single-dose pen device improves patient acceptance and preference. 8

What are the indications, dosing schedule, contraindications, adverse effects, and monitoring recommendations for dulaglutide (Trulicity) in adults with type 2 diabetes?

Help us tailor your experience